short bowel patients treated for two years with glucagon-like peptide 2 (glp-2) compliance, safety, and effects on quality of life短肠患者治疗两年glucagon-like肽2(glp-2)合规、安全,对生活质量的影响.pdfVIP

Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2009, Article ID 425759, 9 pages doi:10.1155/2009/425759 Clinical Study Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life P. B. Jeppesen,1 P. Lund,1 I. B. Gottschalck,1 H. B. Nielsen,2 J. J. Holst,3 J. Mortensen,4 S. S. Poulsen,3 B. Quistorff,3 and P. B. Mortensen1 1 Department of Gastroenterology, Copenhagen University Hospital (Rigshospitalet), 2121 Copenhagen, Denmark 2 Department of Anesthesia, Copenhagen University Hospital (Rigshospitalet), 2100 Copenhagen, Denmark 3 Department of Biomedical Sciences, The Panum Institute, 2200 Copenhagen, Denmark 4 Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital (Rigshospitalet), 2100 Copenhagen, Denmark Correspondence should be addressed to P. B. Jeppesen, bekker@dadlnet.dk Received 24 March 2009; Accepted 29 May 2009 Recommended by Karel Geboes Background and aims. Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients in a short-term study. This study describes safety, compliance, and changes in quality of life in 11 SBS patients at baseline, week 13, 26, and 52 during two years of subcutaneous GLP-2 treatment, 400 microgram TID, intermitted by an 8-week washout period. Methods. Safety and compliance was evaluated during the admissions. The Sickness Impact Profile (SIP), Short Form 36 (SF 36), and Inflammatory Bowel Disease Questionnaire (IBDQ) evaluated quality of life. Results. The predominant adverse event was transient abdominal discomfort in 5 of 11 patients, but in 2, both suffering from Crohns disease, it progressed to abdominal pain and led to discont